The role of antiarrhythmic drugs in prevention of sudden cardiac death.
P J
PJ
Podrid
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use*; D001073:Aprindine / Q000627:therapeutic use; D001145:Arrhythmias, Cardiac / Q000209:etiology; D005117:Cardiac Complexes, Premature / Q000517:prevention & control; D002986:Clinical Trials as Topic; D003645:Death, Sudden / Q000209:etiology; D004206:Disopyramide / Q000627:therapeutic use; D006801:Humans; D008012:Lidocaine / Q000031:analogs & derivatives / Q000627:therapeutic use; D008801:Mexiletine / Q000627:therapeutic use; D009203:Myocardial Infarction / Q000150:complications / Q000188:drug therapy; D010672:Phenytoin / Q000627:therapeutic use; D011342:Procainamide / Q000627:therapeutic use; D011802:Quinidine / Q000627:therapeutic use; D011897:Random Allocation; D016677:Tocainide
D000319:Adrenergic beta-Antagonists; D000889:Anti-Arrhythmia Agents; D008801:Mexiletine; D016677:Tocainide; D001073:Aprindine; D010672:Phenytoin; D008012:Lidocaine; D004206:Disopyramide; D011802:Quinidine; D011342:Procainamide